PLX Protalix BioTherapeutics Inc. (DE)
0.48
+0.03 (+6%)
Previous Close
0.45
Open
0.45
Price To Book
-1.09
Market Cap
71219962
Shares
148,374,921
Volume
613,852
Short Ratio
5.7
Av. Daily Volume
660,856
NewsSee all news
- The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
- Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
- The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
- New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
- Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
SEC filingsSee all SEC filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590513
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590200
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19579458
- 8-K - Current report 19566182
- 8-K - Current report 19520310
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be finalized 2018.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
Pegunigalsidase alfa (PRX-102) BRIDGE
Fabry disease
Phase 3 PK data from open label trial to be presented at WORLDSymposium February 7, 2019.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Latest News
- The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
- Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
- The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
- New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
- Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
- Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market?
- Implied Volatility Surging for Protalix (PLX) Stock Options
- Moving Average Crossover Alert: Protalix BioTherapeutics
- Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
- Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
- Protalix: 3Q Earnings Snapshot
- Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
- The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
- The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs
- Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics
SEC Filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590513
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590200
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19579458
- 8-K - Current report 19566182
- 8-K - Current report 19520310
- 8-K - Current report 19510480
- DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 181242189
- 8-K - Current report 181237010
- 8-K - Current report 181233586
- CT ORDER - Confidential treatment order 181215692